An apoptosis panel for nonalcoholic steatohepatitis diagnosis.
Tamimi TI, Elgouhari HM, Alkhouri N, Yerian LM, Berk MP, Lopez R, Schauer PR, Zein NN, Feldstein AE.
J Hepatol 2011;54:1224-1229.
Nonalcoholic fatty liver disease (NAFLD) is a wide-spectrum disease entity from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis. After Ludwig et al
1 introduced the name of NASH firstly in 1980, the concerns about NASH have been explored intensively. The majority of cryptogenic cirrhosis diagnosed in the past presume the progressed state of NASH. Approximately 90% of abnormal liver function without specific causes such as virus, alcohol, toxic and genetic factor presumes NAFLD.
2 For diagnosis of NAFLD, several causes which can induce hepatic steatosis should be excluded such as protein-calorie malnutrition, starvation, total parenteral nutrition, rapid weight loss, amiodarone, methotraxate, valproic acid, glucocorticoid, calcium-channel blocker, tamoxifen, tetracycline, and aspirin.
2 Although the prevalence of NAFLD is different among countries and races, about 10-20% of general population may have NAFLD.
2
Simple hepatic steatosis is usually thought as a non-progressive condition,
3 but about 5% of hepatic steatosis can progress to NASH.
4 In contrast to hepatic steatosis, approximately 30% of NASH shows the progression of fibrosis within 5 years;
5 about 20% of NASH progresses to cirrhosis during lifetime.
6 Once cirrhosis is developed, the risk of complications of cirrhosis is increased such as ascites, variceal bleeding, hepatic encephalopathy and development of hepatocellular carcinoma.
7 NASH should be discriminated from simple hepatic steatosis because of the above reasons. Liver biopsy is still gold standard for differentiating between steatosis and NASH. The pathologic findings of NASH are macrovesicular steatosis, lobular inflammation, Mallory bodies, ballooning degeneration, and perisinusoidal/perivenular fibrosis. Using these parameters, Brunt et al
8 introduced necroinflammatory grade and fibrosis score system for NASH in 1999. Recently, NASH Clinical Research Network introduced new system in which the degrees of steatosis, lobular inflammation, hepatocyte ballooning and Mallory bodies are scored as NAFLD activity score (NAS).
9 NASH can be differentiated from hepatic steatosis with NAS system. However, liver biopsy is an invasive procedure with significant complication like bleeding. Several non-invasive biomarkers for diagnosis of NASH have been investigated recently. Palekar et al
10 investigated the model for predicting NASH using 8-epi-PGF2α, TGF-β, hyaluronic acid and adiponectin (sensitivity: 73.7%, specificity: 65.7%, positive predictive value: 68.2%, negative predictive value: 68.2%). Poynard et al
11 introduced the model, Steatotest for predicting over 30% steatosis using alanine aminotransferase (ALT), a2-macroglobulin, apolipoprotein A-I, haptoglobin, total bilirubin, γ-glutamyl transpeptidase (GGT), cholesterol, triglycerides, glucose, age, gender and body mass index (BMI) (sensitivity: 90%, specificity: 90%, negative predictive value: 93%, positive predictive value: 63%). FibroTest was introduced for predicting advanced fibrosis (F3, F4) using α2-macroglobulin, apolipoprotein A-I, haptoglobin, total bilirubin, GGT and ALT (positive predictive value: 73%, negative predictive value: 90%).
12 Similarly, NAFLD fibrosis score was investigated for predicting advanced fibrosis using age, hyperglycemia, BMI, platelet count, albumin and aspartate aminotransferase (AST)/ALT ratio (positive predictive value: 82%, negative predictive value: 93%).
13 Several inflammatory mediators are increased in NASH compared to simple hepatic steatosis such as tumor necrosis factor (TNF)-α, interleukin-6 (IL-6), CC-chemokine ligand 2 (CCL-2), and hyaluronic acid.
14-
16
Deregulation of hepatocyte apoptosis is an important mechanism of liver injury and NASH development.
17-
19 Fas has a critical role in apoptosis pathway as a death receptor member of the TNF receptor family. Expression of this membrane protein is increased in NASH patients.
17 Accumulation of free fatty acids in hepatocytes results in up-regulation of Fas in the cell membrane which increases the sensitivity to Fas mediated apoptosis.
20 At the level of mitochondria, apoptosis pathway induces permiabilization of the mitochondrial outer membrane and release of multiple protein from the mitochondrial inner membrane space to cytoplasm.
21 This results in activation of effector caspases (mainly caspase 3) which will cleave substrates in cytoplasm like cytokeratin 18 (CK-18), the major intermediate filament protein of liver, inducing the specific morphologic change of apoptosis.
21 There are several reports showing that the quantification of this caspase generated CK-18 fragments is useful for diagnosis of NASH.
22-
25
In subject study, they investigated the apoptosis panel for non-invasive diagnosis of NASH using these two biomarkers, serum CK-18 fragments and soluble Fas (sFas). Compared to each single biomarker, the combination of two biomarkers, serum CK-18 fragments and sFas showed significantly higher area under curve (AUC) (0.86 in CK-18, 0.86 in sFas and 0.93 in CK-18 with sFas), sensitivity (88%), and specificity (89%) for diagnosis of NASH. The high AUC in the validation group (0.79) indicates the reproducibility of this apoptosis panel. This apoptosis panel for NASH diagnosis is non-invasive, simple, reproducible and reliable method which is needed in real clinical situation. Not only for diagnosis but also for assessment of treatment response and prognosis, this apoptosis panel with serum CK-18 fragments and sFas could be used after proper researches are done.
In conclusion, this diagnostic apoptosis panel including serum CK-18 fragments and sFas for diagnosis of NASH is useful test in clinical practice for noninvasive diagnosis of NASH as a simple, easy to measure, reproducible and reliable method. Further studies are needed to validate the accuracy of this apoptosis panel for NASH diagnosis in each race and country. We need to investigate whether this apoptosis panel could be used for assessment of treatment response and predicting prognosis of NASH.
Abbreviations
nonalcoholic fatty liver disease
nonalcoholic steatohepatitis
γ-glutamyl transpeptidase
aspartate aminotransferase
REFERENCES
- 1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438. 7382552.
- 2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231. 11961152.
- 3. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-121. 16012941.
- 4. Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology 2005;129:375-378. 16012969.
- 5. Fassio E, Alvarez E, Domínguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004;40:820-826. 15382171.
- 6. Edmison J, McCullough AJ. Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis 2007;11:75-104. ix. 17544973.
- 7. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-140. 12105842.
- 8. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474. 10484010.
- 9. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321. 15915461.
- 10. Palekar NA, Naus R, Larson SP, Ward J, Harrison SA. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int 2006;26:151-156. 16448452.
- 11. Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005;4:10. 16375767.
- 12. Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006;6:6. 16503961.
- 13. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846-854. 17393509.
- 14. Haukeland JW, Damås JK, Konopski Z, Løberg EM, Haaland T, Goverud I, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 2006;44:1167-1174. 16618517.
- 15. Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2005;25:779-786. 15998429.
- 16. Abiru S, Migita K, Maeda Y, Daikoku M, Ito M, Ohata K, et al. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int 2006;26:39-45. 16420507.
- 17. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003;125:437-443. 12891546.
- 18. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006;44:27-33. 16799979.
- 19. Feldstein AE, Gores GJ. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci 2005;10:3093-3099. 15970563.
- 20. Feldstein AE, Canbay A, Guicciardi ME, Higuchi H, Bronk SF, Gores GJ. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol 2003;39:978-983. 14642615.
- 21. Malhi H, Gores GJ. Cellular and molecular mechanisms of liver injury. Gastroenterology 2008;134:1641-1654. 18471544.
- 22. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009;50:1072-1078. 19585618.
- 23. Diab DL, Yerian L, Schauer P, Kashyap SR, Lopez R, Hazen SL, et al. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol 2008;6:1249-1254. 18995215.
- 24. Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M, Stepanova M, et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 2008;18:1430-1437. 18500507.
- 25. Malik R, Chang M, Bhaskar K, Nasser I, Curry M, Schuppan D, et al. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2009;24:564-568. 19378390.
Citations
Citations to this article as recorded by
- Lacticaseibacillus paracsei HY7207 Alleviates Hepatic Steatosis, Inflammation, and Liver Fibrosis in Mice with Non-Alcoholic Fatty Liver Disease
Hyeon-Ji Kim, Hye-Jin Jeon, Dong-Gun Kim, Joo-Yun Kim, Jae-Jung Shim, Jae-Hwan Lee
International Journal of Molecular Sciences.2024; 25(18): 9870. CrossRef - 15-Lipoxygenase metabolites of α-linolenic acid, [13-(S)-HPOTrE and 13-(S)-HOTrE], mediate anti-inflammatory effects by inactivating NLRP3 inflammasome
Naresh Kumar, Geetika Gupta, Kotha Anilkumar, Naireen Fatima, Roy Karnati, Gorla Venkateswara Reddy, Priyanka Voori Giri, Pallu Reddanna
Scientific Reports.2016;[Epub] CrossRef
